Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom.

Sheehan’s Syndrome Presenting as Major Depressive Disorder

Sheehan’s syndrome or Simmond’s disease is a rare endocrine disorder seen in clinical practice. The clinical spectrum is diverse and a high index of suspicion together with a good clinical acumen and proper diagnostic approach helps in early diagnosis and prompt treatment of this endocrinopathy. Sheehan’s syndrome presenting as a major depressive disorder finds less mention in the literature.Th...

A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom

کارکردهای عصب ـ روانشناختی در اقدام‌کنندگان به خودکشی مبتلا به اختلال افسردگی اساسی

 AbstractObjectives: Neuropsychological dysfunction in major depressive disorder may be associated with the suicide risk in these patients. In this study, neuropsychological functions in patients with major depre-ssion and at least one prior suicide attempt, in patients with major depre-ssion and no history of suicide attempt, and healthy controls were compared. Method: In this causal or ex pos...

Vortioxetine versus placebo for treatment of major depressive disorder

Introduction: Major depressive disorder is a common mental condition associated with substantial morbidity and economic burden. Approved by the FDA in September 2013 for treatment of episodes of major depressive disorder, Vortioxetine is one of the newer options available in this important area of therapeutics. Materials and methods: A comprehensive literature search (PubMed, the Cochrane libr...

Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder.

We conducted a cost-effectiveness analysis of acute major depressive disorder (MDD) using serotonin-norepinephrine reuptake inhibitors (SNRIs; venlafaxine), selective serotonin reuptake inhibitors (SSRIs; fluoxetine, fluvoxamine, sertraline, paroxetine), or tricyclic antidepressants (TCAs; amitriptyline, imipramine, desipramine, nortriptyline). A decision-tree model over 6 months was constructe...